BBH Fact Sheet: VanEck Biotech ETF
Share
$239.49
close, Nov 20, 2026
Over the year to Nov 19, 2026, BBH returned +28.4% in total and charged 0.35% a year.
- 1-year total return
- +27.1%
- to Nov 20, 2026
- Expense ratio
- 0.35%
- a year
- Net assets
- $509m
- on Nov 19, 2026
Growth of $10,000, 1 year
BBH $12,842 +28.4% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−4.4%
3 months−0.7%
Year to date+26.5%
1 year+27.1%
3 years+62.5%
5 years+26.9%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Amgen Inc16.42%
Gilead Sciences Inc14.80%
Vertex Pharmaceuticals Inc8.23%
Regeneron Pharmaceuticals Inc7.95%
Moderna Inc6.31%
Argenx Se4.53%
Iqvia Holdings Inc4.18%
Natera Inc3.77%
Revolution Medicines Inc3.29%
Beone Medicines Ltd3.03%
BBH top ten by weight, 72.5% of the fund, of its 25 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 25 stocks in biotech, 65% of its weight in S&P 500 companies · First traded Dec 20, 2011 · Benchmark Its own holdings, as of Nov 18, 2026